DF Dent & Co. Inc. Sells 7,515 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

DF Dent & Co. Inc. cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 6.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 112,530 shares of the medical research company’s stock after selling 7,515 shares during the period. DF Dent & Co. Inc.’s holdings in Charles River Laboratories International were worth $20,773,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of CRL. Cinctive Capital Management LP acquired a new position in Charles River Laboratories International in the 4th quarter valued at about $2,262,000. Bryce Point Capital LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $535,000. Huntington National Bank lifted its holdings in Charles River Laboratories International by 120.6% during the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company’s stock worth $55,000 after purchasing an additional 164 shares during the last quarter. Groupama Asset Managment boosted its stake in Charles River Laboratories International by 155.5% in the 4th quarter. Groupama Asset Managment now owns 3,416 shares of the medical research company’s stock valued at $627,000 after purchasing an additional 2,079 shares during the period. Finally, Trexquant Investment LP grew its holdings in Charles River Laboratories International by 440.2% in the 4th quarter. Trexquant Investment LP now owns 100,277 shares of the medical research company’s stock valued at $18,511,000 after buying an additional 81,714 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CRL. Robert W. Baird reduced their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Bank of America lowered their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. UBS Group reiterated a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, JPMorgan Chase & Co. lowered their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. One research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $189.77.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster acquired 6,075 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Up 2.3 %

CRL opened at $149.30 on Thursday. The company has a market cap of $7.63 billion, a P/E ratio of 995.33, a PEG ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company’s 50 day moving average is $163.57 and its 200-day moving average is $181.69. Charles River Laboratories International, Inc. has a 1-year low of $142.76 and a 1-year high of $264.71.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter last year, the business posted $2.46 earnings per share. The company’s quarterly revenue was down 1.1% on a year-over-year basis. Equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).